Rhythm Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $989.68 million
- Book Value:
- Revenue TTM:
- $23.64 million
- Operating Margin TTM:
- Gross Profit TTM:
- $21.51 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Rhythm Pharmaceuticals Inc had its IPO on 2017-10-05 under the ticker symbol RYTM.
The company operates in the Healthcare sector and Biotechnology industry. Rhythm Pharmaceuticals Inc has a staff strength of 177 employees.
Shares of Rhythm Pharmaceuticals Inc opened at $17.5 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $16.95 - $18.03, and closed at $17.66.
This is a +1.26% increase from the previous day's closing price.
A total volume of 1,194,337 shares were traded at the close of the day’s session.
In the last one week, shares of Rhythm Pharmaceuticals Inc have increased by +4.62%.
Rhythm Pharmaceuticals Inc's Key Ratios
Rhythm Pharmaceuticals Inc has a market cap of $989.68 million, indicating a price to book ratio of 5.0137 and a price to sales ratio of 95.689.
In the last 12-months Rhythm Pharmaceuticals Inc’s revenue was $23.64 million with a gross profit of $21.51 million and an EBITDA of $-177484992. The EBITDA ratio measures Rhythm Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Rhythm Pharmaceuticals Inc’s operating margin was -757.92% while its return on assets stood at -31.45% with a return of equity of -66.05%.
In Q4, Rhythm Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 383.8%.
Rhythm Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-3.49 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Rhythm Pharmaceuticals Inc’s profitability.
Rhythm Pharmaceuticals Inc stock is trading at a EV to sales ratio of 63.855 and a EV to EBITDA ratio of -3.7184. Its price to sales ratio in the trailing 12-months stood at 95.689.
Rhythm Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $382.48 million
- Total Liabilities
- $39.81 million
- Operating Cash Flow
- Capital Expenditure
- $4.00 million
- Dividend Payout Ratio
Rhythm Pharmaceuticals Inc ended 2023 with $382.48 million in total assets and $0 in total liabilities. Its intangible assets were valued at $382.48 million while shareholder equity stood at $264.26 million.
Rhythm Pharmaceuticals Inc ended 2023 with $75.81 million in deferred long-term liabilities, $39.81 million in other current liabilities, 56000.00 in common stock, $-710058000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $127.68 million and cash and short-term investments were $333.29 million. The company’s total short-term debt was $684,000 while long-term debt stood at $1.34 million.
Rhythm Pharmaceuticals Inc’s total current assets stands at $354.24 million while long-term investments were $16.66 million and short-term investments were $205.61 million. Its net receivables were $6.22 million compared to accounts payable of $4.80 million and inventory worth $2.92 million.
In 2023, Rhythm Pharmaceuticals Inc's operating cash flow was $-40775000.00 while its capital expenditure stood at $4.00 million.
Comparatively, Rhythm Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Rhythm Pharmaceuticals Inc stock is currently trading at $17.66 per share. It touched a 52-week high of $34.99 and a 52-week low of $34.99. Analysts tracking the stock have a 12-month average target price of $38.78.
Its 50-day moving average was $23.99 and 200-day moving average was $21.99 The short ratio stood at 9.92 indicating a short percent outstanding of 0%.
Around 38.9% of the company’s stock are held by insiders while 11219.1% are held by institutions.
Frequently Asked Questions About Rhythm Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company’s lead product candidate is IMCIVREE, a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.